Donovan F M, Vaughan P J, Cunningham D D
Department of Microbiology and Molecular Genetics, University of California, Irvine 92717.
J Biol Chem. 1994 Jun 24;269(25):17199-205.
Recent studies have shown that serine protease inhibitors can be regulated in their activity, specificity, and location by glycoprotein or extracellular matrix (ECM) co-factors. Protease nexin-1 (PN-1) is a member of the serpin superfamily of serine protease inhibitors which can rapidly inhibit thrombin, urokinase, and plasmin. PN-1 binds tightly to and is regulated by the ECM. This interaction accelerates the inhibition of thrombin by PN-1 and blocks urokinase and plasmin inhibition by PN-1. Previous work showed that heparan sulfate proteoglycan is largely responsible for the acceleration of thrombin inhibition by PN-1. Our current studies were directed at identifying ECM component(s) that decreased the ability of PN-1 to inhibit urokinase and plasmin. These studies showed that collagen type IV decreased the formation of SDS-stable complexes between urokinase or plasmin and PN-1 without affecting formation of complexes between thrombin and PN-1. The second order rate constant for inhibition of urokinase by PN-1 was markedly decreased with increasing collagen type IV, whereas the second order rate constant for inhibition of thrombin by PN-1 was unaffected by addition of collagen type IV. Other ECM components (collagen type I, vitronectin, fibronectin, and heat-denatured collagen type IV) did not affect complex formation or the rate of inhibition of proteases by PN-1, indicating that these effects were specific to collagen type IV. Binding of PN-1 to immobilized collagen type IV was demonstrated using an enzyme-linked immunosorbent assay; the concentration of PN-1 necessary to obtain 50% saturation of the immobilized collagen type IV binding sites was approximately 15 nM. Collagen type IV was also copurified with PN-1 from fibroblast-conditioned medium. These results demonstrate a novel regulation of serpin specificity in which an ECM co-factor decreased the inhibition of certain proteases by the serpin without affecting the inhibition of its target protease.
最近的研究表明,丝氨酸蛋白酶抑制剂的活性、特异性和位置可由糖蛋白或细胞外基质(ECM)辅助因子调节。蛋白酶nexin-1(PN-1)是丝氨酸蛋白酶抑制剂丝氨酸蛋白酶抑制剂超家族的成员,可迅速抑制凝血酶、尿激酶和纤溶酶。PN-1与ECM紧密结合并受其调节。这种相互作用加速了PN-1对凝血酶的抑制,并阻断了PN-1对尿激酶和纤溶酶的抑制。先前的研究表明,硫酸乙酰肝素蛋白聚糖在很大程度上负责PN-1对凝血酶抑制的加速作用。我们目前的研究旨在确定降低PN-1抑制尿激酶和纤溶酶能力的ECM成分。这些研究表明,IV型胶原减少了尿激酶或纤溶酶与PN-1之间SDS稳定复合物的形成,而不影响凝血酶与PN-1之间复合物的形成。随着IV型胶原的增加,PN-1抑制尿激酶的二级速率常数显著降低,而PN-1抑制凝血酶的二级速率常数不受IV型胶原添加的影响。其他ECM成分(I型胶原、玻连蛋白、纤连蛋白和热变性IV型胶原)不影响复合物的形成或PN-1对蛋白酶的抑制速率,表明这些作用对IV型胶原具有特异性。使用酶联免疫吸附测定法证明了PN-1与固定化IV型胶原的结合;使固定化IV型胶原结合位点达到50%饱和所需的PN-1浓度约为15 nM。IV型胶原也从成纤维细胞条件培养基中与PN-1一起共纯化。这些结果证明了丝氨酸蛋白酶抑制剂特异性的一种新调节方式,即ECM辅助因子降低了丝氨酸蛋白酶抑制剂对某些蛋白酶的抑制作用,而不影响其对靶蛋白酶的抑制作用。